As we heard over at the hub, at least one short has covered on this new Aspire deal. This certainly eliminates any hope they had of a quick victory against IPIX. There just isn't much meat left on the bone for those that shorted at $3-4. If you've already made 50-80% of your potential gains on that short play, it's wise to leave the rest on the table considering how long IPIX could stay solvent even without any successes.
That's not even mentioning the foreboding risk of the trial successes already in the bag and those yet to come. The shorts carried the day in 2015, 2016 and possibly in 2017 but the shoe is likely to be on the other foot in 2018.
Go IPIX!
(0)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
All my posts are my own personal opinion and speculation. They should not be used as the basis for any investment decision. No, I am not Scottsmith.